Saturday 17 October 2026
Export ZVRA’s income statement to Excel — free account
Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.
9.95
0.32
−3.12%
Follow ZVRA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 2 | 3 | 3 | 6 | — | — | — | — | — |
P/E ratio |
6.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
4.65 | 16.34 | 8.82 | 15.38 | 9.05 | 3.36 | 0.00 | — | — | — |
Altman Z-Score |
0.63 | (3.43) | (2.69) | (2.22) | 25.31 | (32.31) | (37.65) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 25.14 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(0.84) | (10.32) | (8.41) | (5.92) | 22.23 | (78.94) | (89.20) | — | — | — |
Beneish M-Score |
1.46 | (3.86) | (1.17) | 7.85 | (2.32) | (6.75) | — | — | — | — |
P/Operating CF |
89.85 | (23.74) | (14.98) | (35.01) | (305.73) | (42.10) | (3.62) | — | — | — |
P/B ratio |
3.20 | 9.72 | 3.91 | 2.08 | 2.04 | 0.00 | 0.00 | — | — | — |
Price to Tangible BV |
3.45 | 0.00 | 0.00 | 2.08 | 2.04 | 0.00 | 0.00 | — | — | — |
EV/Sales |
3.80 | 17.51 | 7.91 | 8.53 | 5.18 | 8.18 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 18.26 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(252.94) | (5.93) | (6.48) | (4.63) | 14.23 | (56.06) | (3.60) | — | — | — |
EV/FCF |
(203.63) | (5.91) | (6.42) | (4.61) | 14.40 | (55.12) | (3.60) | — | — | — |
Quick Ratio |
5.46 | 2.35 | 1.15 | 7.58 | 26.92 | 0.92 | 1.00 | 1.82 | 3.84 | 11.12 |
Current Ratio |
5.68 | 2.53 | 1.18 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.20 |
Net Debt/EBITDA |
39.03 | 0.12 | 0.51 | 1.67 | (13.61) | (21.15) | (4.04) | (1.12) | (1.63) | (0.65) |
Debt/Assets |
21.75% | 33.41% | 24.82% | 11.52% | 1.21% | 610.57% | 741.06% | 306.77% | 178.21% | 108.36% |
Debt/Equity |
0.40 | 1.50 | 0.69 | 0.18 | 0.01 | (1.03) | (1.05) | (1.23) | (1.63) | (4.92) |
Asset Turnover |
0.46 | 0.13 | 0.19 | 0.08 | 0.40 | 1.22 | 0.69 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
(0.02) | 0.66 | 0.73 | 0.70 | (0.17) | 0.15 | 0.97 | 0.96 | 0.76 | 1.80 |
Capex/Depreciation |
(0.01) | 0.00 | (0.29) | (0.10) | (0.25) | (0.01) | (0.01) | (0.01) | (0.10) | (0.36) |
Interest Coverage |
(7.89) | (11.84) | (33.05) | (127.06) | 20.56 | (0.79) | (3.12) | (7.89) | (4.55) | (5.26) |
| 79.85% | (207.84%) | (67.23%) | (26.48%) | (207.22%) | 18.12% | 34.78% | 91.01% | 113.86% | 114.63% | |
| 33.52% | (60.21%) | (32.02%) | (21.57%) | (87.27%) | (117.52%) | (131.65%) | (142.59%) | (63.18%) | (23.68%) | |
ROIC |
(153.83%) | (183.25%) | (84.03%) | (478.56%) | 29.49% | 0.00% | 0.00% | 0.00% | 0.00% | (529.65%) |
Return on Tangible Assets |
42.12% | (201.67%) | (330.01%) | (32.81%) | (56.30%) | (676.92%) | (814.14%) | (419.20%) | (119.22%) | (23.70%) |
Average Days of Receivables |
79.73 | 162.45 | 230.97 | 298.11 | 19.47 | 70.84 | 53.02 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
11.97% | 178.28% | 144.95% | 194.89% | 35.47% | 66.55% | 151.22% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
72.90% | 232.37% | 124.96% | 148.00% | 30.37% | 65.84% | 84.24% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.04 | 0.41 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
11.94% | 65.14% | 22.51% | 44.46% | 9.56% | 20.27% | 34.35% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.19 | (0.14) | (0.10) | 0.34 | 0.42 | (1.55) | (6.95) | — | — | — |
Graham Number |
9.28 | 0.00 | 0.00 | 0.00 | 0.00 | 34.81 | 112.82 | — | — | — |
Earnings Yield |
15.29% | (26.86%) | (18.38%) | (17.05%) | (32.75%) | (28.82%) | (232.34%) | — | — | — |
Free Cash Flow Yield |
(0.40%) | (18.14%) | (13.97%) | (12.04%) | 3.98% | (4.42%) | (211.62%) | — | — | — |
Revenue per Share |
1.92 | 0.51 | 0.77 | 0.29 | 0.96 | 3.34 | 6.93 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.03) | (1.51) | (0.95) | (0.54) | 0.35 | (0.49) | (12.81) | (48.37) | (36.14) | (32.63) |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | 0.00 | (0.01) | (0.01) | (0.02) | (0.20) | (0.70) |
Free Cash Flow per Share |
(0.04) | (1.51) | (0.95) | (0.55) | 0.35 | (0.50) | (12.82) | (48.39) | (36.34) | (33.34) |
Cash per Share |
3.45 | 1.50 | 1.91 | 2.40 | 3.77 | 1.09 | 1.92 | 19.34 | 46.11 | 75.49 |
Shareholders Equity per Share |
2.80 | 0.86 | 1.75 | 2.18 | 4.27 | (16.68) | (40.18) | (59.40) | (62.80) | (20.49) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.80 | 0.86 | 1.75 | 2.18 | 4.27 | (16.68) | (40.18) | (59.40) | (62.80) | (20.49) |
Free Cash Flow |
(1.98) | (69.66) | (33.83) | (18.81) | 10.34 | (1.97) | (23.76) | (54.22) | (33.28) | (30.41) |
Working Capital |
183.73 | 51.96 | 13.22 | 80.81 | 110.83 | 0.85 | 1.54 | 11.72 | 34.39 | 67.72 |
Capital Expenditures |
(0.39) | — | (0.30) | (0.09) | (0.10) | (0.03) | (0.03) | (0.02) | (0.18) | (0.64) |
Net Current Asset Value |
92.93 | (52.43) | (23.52) | 52.61 | 109.23 | (69.24) | (77.99) | (69.59) | (64.08) | (29.23) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 19.22 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 33.54 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
121.96 | 15.45 | 1.37 | 1.19 | 0.46 | 2.48 | 1.33 | 1.11 | 0.95 | 0.91 |
Cash ROIC |
(0.49%) | (41.30%) | (19.63%) | (10.98%) | 4.29% | (31.06%) | (341.32%) | (145.96%) | (42.56%) | (21.40%) |
Accounts Receivable Turnover |
6.31 | 1.69 | 2.14 | 2.07 | 13.95 | 5.98 | 12.81 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.89 | 0.28 | 0.13 | 0.05 | 0.43 | 0.23 | 0.44 | 0.04 | 0.05 | 0.03 |
Inventory Turnover |
8.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
256.84 | 1,252.72 | 4,770.87 | 10,142.73 | 538.55 | 1,859.12 | 608.66 | 9,397.62 | 8,554.69 | 13,440.34 |
Days of Inventory on Hand |
38.53 | 96.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
16.88 | 13.94 | 12.84 | 4.91 | 2.05 | 2.22 | 1.00 | 1.07 | 3.50 | 3.54 |
Average Payables |
18.53 | 26.93 | 17.29 | 4.60 | 4.84 | 5.78 | 6.63 | 8.11 | 7.16 | 5.68 |
Average Inventory |
1.86 | — | — | — | — | — | — | — | — | — |
Average Assets |
231.43 | 175.23 | 143.83 | 124.14 | 72.08 | 10.86 | 18.63 | 39.60 | 68.67 | 69.74 |
Average Common Equity |
97.16 | 50.77 | 68.49 | 101.12 | 30.35 | (70.43) | (70.51) | (62.04) | (38.11) | (14.41) |
Columns are period end dates